Article

January 2, 2013

Robert Gamble Talks about the Challenges Payers and Providers Face in Oncology Management

In this video, Robert Bo Gamble, Director, Strategic Practice Initiatives, Community Oncology Alliance, Washington, DC, says that it is critical for payers and providers to come together in oncology management.

In this video, Robert “Bo” Gamble, Director, Strategic Practice Initiatives, Community Oncology Alliance, Washington, DC, says that it is critical for payers and providers to come together in oncology management. Consensus, communication, and collaboration between payers and providers is key to effectively working together in cancer care.

Related Videos

John Michael O'Brien, PharmD, MPH

Richard J. Nowak, MD, MS, Yale School of Medicine

Naim Alkhouri, MD

Christine Funke, MD

Drs Lillian L. Siu and Matthew G. Vander Heiden

Jaime Almandoz, MD, MBA

Martin Edelman, MD

Benjamin Chen, MD, PhD

Frederick L Locke, MD, Moffitt

Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)

Related Content

Researchers analyzed matched cohorts of patients who received either decitabine-cedazuridine with venetoclax or decitabine-cedazuridine alone to determine how the addition of venetoclax impacts outcomes in higher-risk MDS and CMML. |Image credit: syahrir - stock.adobe.com

April 25th 2025

Adding Venetoclax to Decitabine-Cedazuridine Improves Response in MDS Subgroups

Adding venetoclax to decitabine-cedazuridine significantly enhanced response rates in patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia.

April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD

On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.

Q&A with Sid Patel, MD

April 24th 2025

Abelacimab Demonstrates Safety and Efficacy for Patients With AFib of All Ages: Sid Patel, MD

Kyle Munz Siddharth M. Patel, MD, MPH

The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated Sid Patel, MD.

Managed Care Cast Thumbnail

April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

Diabetes monitoring | Image credit: abidika - stock.adobe.com

April 23rd 2025

New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

A new study has found increased risks for liver, pancreatic, and bowel cancers following a new diagnosis of type 2 diabetes—but not all obesity-related cancers show a link.

Vitamin D | Image credit: Galina Zhigalova - stock.adobe.com

April 23rd 2025

Vitamin D’s Potential Role in Colorectal Cancer Prevention, Immune Health

Emerging research highlights how vitamin D boosts immunity and reduces colorectal cancer (CRC) risk by regulating inflammation and cell growth.

Related Content

Researchers analyzed matched cohorts of patients who received either decitabine-cedazuridine with venetoclax or decitabine-cedazuridine alone to determine how the addition of venetoclax impacts outcomes in higher-risk MDS and CMML. |Image credit: syahrir - stock.adobe.com

April 25th 2025

Adding Venetoclax to Decitabine-Cedazuridine Improves Response in MDS Subgroups

Adding venetoclax to decitabine-cedazuridine significantly enhanced response rates in patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia.

April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD

On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.

Q&A with Sid Patel, MD

April 24th 2025

Abelacimab Demonstrates Safety and Efficacy for Patients With AFib of All Ages: Sid Patel, MD

Kyle Munz Siddharth M. Patel, MD, MPH

The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated Sid Patel, MD.

Managed Care Cast Thumbnail

April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

Diabetes monitoring | Image credit: abidika - stock.adobe.com

April 23rd 2025

New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

A new study has found increased risks for liver, pancreatic, and bowel cancers following a new diagnosis of type 2 diabetes—but not all obesity-related cancers show a link.

Vitamin D | Image credit: Galina Zhigalova - stock.adobe.com

April 23rd 2025

Vitamin D’s Potential Role in Colorectal Cancer Prevention, Immune Health

Emerging research highlights how vitamin D boosts immunity and reduces colorectal cancer (CRC) risk by regulating inflammation and cell growth.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions